PMID- 28906590
OWN - NLM
STAT- MEDLINE
DCOM- 20180320
LR  - 20221207
IS  - 1759-7714 (Electronic)
IS  - 1759-7706 (Print)
IS  - 1759-7706 (Linking)
VI  - 8
IP  - 6
DP  - 2017 Nov
TI  - FGF19 genetic amplification as a potential therapeutic target in lung squamous 
      cell carcinomas.
PG  - 655-665
LID - 10.1111/1759-7714.12504 [doi]
AB  - BACKGROUND: Although FGF19 gene aberrations are associated with carcinogenesis 
      and progression in human cancers, the roles of FGF19 genetic amplification and 
      expression in Chinese patients with lung squamous cell carcinoma (LSCC) and FGF19 
      amplification as a potential therapeutic target for LSCC are not well understood. 
      METHODS: Fluorescence in situ hybridization analysis and quantitative 
      real-time-PCR was used to detect FGF19 genetic amplification and FGF19 messenger 
      RNA expression in LSCC tumor and paired adjacent samples. Small interfering RNA 
      and short hairpin RNA were used to knockdown FGF19 in vitro and in vivo. RESULTS: 
      FGF19 amplification was identified in a subset of LSCC patients (37.5%, 15/40), 
      and upregulation of FGF19 expression was found in 60% (24/40) of tumor tissues 
      compared to adjacent non-tumorous tissues. Correlation analysis with 
      clinicopathologic parameters showed that FGF19 upregulation was significantly 
      associated with heavy smoking. Small interfering RNA knockdown of FGF19 led to 
      the significant inhibition of cell growth and induced apoptosis in LSCC cells 
      carrying the amplified FGF19 gene, but these effects was not observed in 
      non-amplified LSCC cells. Interfering FGF19 expression with short hairpin RNA 
      also resulted in tumor growth inhibition and induced apoptosis in LSCC xenografts 
      with amplified FGF19 in tumor cells. CONCLUSION: Our results suggested that FGF19 
      signaling activation is required for cell growth and survival of FGF19 amplified 
      LSCC cells, both in vitro and in vivo. Intervention of FGF19 activation could be 
      a potential therapeutic strategy for LSCC patients with FGF19 amplification.
CI  - (c) 2017 The Authors. Thoracic Cancer published by China Lung Oncology Group and 
      John Wiley & Sons Australia, Ltd.
FAU - Zhang, Xiaochen
AU  - Zhang X
AD  - Department of Medical Oncology, The First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou, China.
FAU - Kong, Mei
AU  - Kong M
AD  - Department of Pathology, The First Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, China.
FAU - Zhang, Zhen
AU  - Zhang Z
AD  - Department of Oncology, Hangzhou Cancer Hospital, Hangzhou, China.
FAU - Xu, Suzhen
AU  - Xu S
AD  - Department of Medical Oncology, The First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou, China.
FAU - Yan, Feifei
AU  - Yan F
AD  - Department of Medical Oncology, The First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou, China.
FAU - Wei, Liyuan
AU  - Wei L
AD  - Department of Medical Oncology, The First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou, China.
FAU - Zhou, Jianying
AU  - Zhou J
AUID- ORCID: 0000-0002-8924-935X
AD  - Department of Respiratory Disease, Thoracic Disease Centre, The First Affiliated 
      Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20170914
PL  - Singapore
TA  - Thorac Cancer
JT  - Thoracic cancer
JID - 101531441
RN  - 0 (FGF19 protein, human)
RN  - 62031-54-3 (Fibroblast Growth Factors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Apoptosis
MH  - Asian People/genetics
MH  - Carcinoma, Squamous Cell/*genetics
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - China/epidemiology
MH  - Female
MH  - Fibroblast Growth Factors/*genetics
MH  - *Gene Amplification
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/*genetics
MH  - Male
MH  - Middle Aged
MH  - Smoking/epidemiology
MH  - Up-Regulation
PMC - PMC5668513
OTO - NOTNLM
OT  - Apoptosis
OT  - FGF19
OT  - cell proliferation
OT  - genetic amplification
OT  - lung squamous cell carcinoma
EDAT- 2017/09/15 06:00
MHDA- 2018/03/21 06:00
PMCR- 2017/11/01
CRDT- 2017/09/15 06:00
PHST- 2017/07/06 00:00 [received]
PHST- 2017/08/08 00:00 [revised]
PHST- 2017/08/09 00:00 [accepted]
PHST- 2017/09/15 06:00 [pubmed]
PHST- 2018/03/21 06:00 [medline]
PHST- 2017/09/15 06:00 [entrez]
PHST- 2017/11/01 00:00 [pmc-release]
AID - TCA12504 [pii]
AID - 10.1111/1759-7714.12504 [doi]
PST - ppublish
SO  - Thorac Cancer. 2017 Nov;8(6):655-665. doi: 10.1111/1759-7714.12504. Epub 2017 Sep 
      14.